Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

ClinicalTrials.gov ID: NCT02650986

Public ClinicalTrials.gov record NCT02650986. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced Malignancies

Study identification

NCT ID: NCT02650986
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Roswell Park Cancer Institute; Other
Enrollment: 15 participants

Conditions and interventions

Conditions

Interventions

Cyclophosphamide Drug
Decitabine Drug
Laboratory Biomarker Analysis Other
Leukapheresis Procedure
TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes Biological

Drug · Other · Procedure + 1 more

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 13, 2017
Primary completion: Mar 3, 2021
Completion: Jul 13, 2032
Last update posted: Jun 16, 2025

2017 – 2032

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Roswell Park Cancer Institute	Buffalo	New York	14263	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02650986, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 16, 2025 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02650986 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →